This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2003 Dec;27(12):1167.

doi: 10.1016/s0145-2126(03)00101-2.

Effects of lower dose of imatinib to CML patients

Akira Horikoshi, Kazuhiro Takei, Shigemasa Sawada

PMID: 12921957
DOI: 10.1016/s0145-2126(03)00101-2

Effects of lower dose of imatinib to CML patients

Akira Horikoshi et al. Leuk Res. 2003 Dec.

. 2003 Dec;27(12):1167.

doi: 10.1016/s0145-2126(03)00101-2.

Authors

Akira Horikoshi, Kazuhiro Takei, Shigemasa Sawada

PMID: 12921957
DOI: 10.1016/s0145-2126(03)00101-2

No abstract available

PubMed Disclaimer

Comment in

Late-onset marrow aplasia due to imatinib in newly diagnosed chronic phase chronic myeloid leukaemia.
Chng WJ, Tan LH. Chng WJ, et al. Leuk Res. 2005 Jun;29(6):719-20. doi: 10.1016/j.leukres.2004.11.017. Leuk Res. 2005. PMID: 15863215 No abstract available.

Similar articles

Imatinib mesylate (STI 571)--a new oral target therapy for chronic myelogenous leukemia (CML).
Chrobák L, Voglová J. Chrobák L, et al. Acta Medica (Hradec Kralove). 2003;46(3):85-9. Acta Medica (Hradec Kralove). 2003. PMID: 14677715 Review.
Specific targeted therapy of chronic myelogenous leukemia with imatinib.
Deininger MW, Druker BJ. Deininger MW, et al. Pharmacol Rev. 2003 Sep;55(3):401-23. doi: 10.1124/pr.55.3.4. Epub 2003 Jul 17. Pharmacol Rev. 2003. PMID: 12869662 Review.
Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.
Ishikawa I, Kato C, Harigae H, Sugawara T, Tomiya Y, Yamada M, Ishizawa K, Kameoka J, Miyamura K, Sasaki T. Ishikawa I, et al. Tohoku J Exp Med. 2006 Dec;210(4):355-63. doi: 10.1620/tjem.210.355. Tohoku J Exp Med. 2006. PMID: 17146202 Clinical Trial.
New drug targets genetic malfunction in chronic myeloid leukemia.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2001 Jul 15;58(14):1282. doi: 10.1093/ajhp/58.14.1282. Am J Health Syst Pharm. 2001. PMID: 11471471 No abstract available.
[TKI therapy for CML].
Ohnishi K. Ohnishi K. Rinsho Ketsueki. 2011 Jul;52(7):452-9. Rinsho Ketsueki. 2011. PMID: 21821976 Review. Japanese. No abstract available.

See all similar articles

Cited by

Tyrosine Kinase Inhibitors Available for Chronic Myeloid Leukemia: Efficacy and Safety.
García-Gutiérrez V, Hernández-Boluda JC. García-Gutiérrez V, et al. Front Oncol. 2019 Jul 3;9:603. doi: 10.3389/fonc.2019.00603. eCollection 2019. Front Oncol. 2019. PMID: 31334123 Free PMC article. Review.
Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients.
Li QB, Chen C, Chen ZC, Wang HX, Wu YL, You Y, Zou P. Li QB, et al. Acta Pharmacol Sin. 2010 Aug;31(8):999-1004. doi: 10.1038/aps.2010.79. Epub 2010 Jul 19. Acta Pharmacol Sin. 2010. PMID: 20644548 Free PMC article. Clinical Trial.
Late response to low-dose imatinib in patients with chronic phase chronic myeloid leukemia.
Takami A, Ohtake S, Morishita E, Terasaki Y, Fukushima T, Kurokawa T, Sugimori N, Matano S, Ohata K, Saito C, Yamaguchi M, Hosokawa K, Yamazaki H, Kondo Y, Nakao S. Takami A, et al. Int J Hematol. 2012 Sep;96(3):357-63. doi: 10.1007/s12185-012-1155-1. Epub 2012 Aug 15. Int J Hematol. 2012. PMID: 22893108
Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.
Chuah CT, Nakamae H, Shen ZX, Bradley-Garelik MB, Kim DW. Chuah CT, et al. Leuk Lymphoma. 2014 Sep;55(9):2093-100. doi: 10.3109/10428194.2013.866663. Epub 2014 Mar 12. Leuk Lymphoma. 2014. PMID: 24289108 Free PMC article. Clinical Trial.
Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan.
Nagai T, Takeuchi J, Dobashi N, Kanakura Y, Taniguchi S, Ezaki K, Nakaseko C, Hiraoka A, Okada M, Miyazaki Y, Motoji T, Higashihara M, Tsukamoto N, Kiyoi H, Nakao S, Shinagawa K, Ohno R, Naoe T, Ohnishi K, Usui N. Nagai T, et al. Int J Hematol. 2010 Jul;92(1):111-7. doi: 10.1007/s12185-010-0621-x. Epub 2010 Jun 25. Int J Hematol. 2010. PMID: 20577839 Clinical Trial.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information